Description

Despite clear evidence regarding the importance of a tumor's molecular signature in treatment algorithms, too few clinicians routinely obtain such information. This webcast will educate clinicians regarding the biochemical pathways that lead to trastuzumab resistance in HER2-positive tumors and current options to overcome such resistance or other options to increase progression-free survival.

Learning Objectives

At the end of this educational activity, participants should be able to:
  • Describe currently available molecular tests for breast tumors and the implications of these results for managing treatment-resistant breast cancer

Target Audience

This continuing medical education web-based activity is intended for community oncologists, surgical oncologists, radiation oncologists, pathologists, oncology nurses, and other health care professionals involved in the care and treatment of women with breast cancer.

Faculty

  • Clinical Director, the Breast Oncology Program, the MGH Cancer Center, Massachusetts General Hospital
    Assistant Professor in Medicine, Harvard Medical School

CME Information

This program is not accredited.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. CME credit is not being offered for this activity.

Credit Designation

Even though this event is not accredited, providing information regarding planning, disclosure, and conflict of interest is important to us. Some providers may be able to claim Category 2 CME credit for participating in this activity.


Policy on Faculty and Provider Disclosure

It is the policy of The Society for Translational Oncology (STO) that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. The Society for Translational Oncology (STO) has established policies in place that identify and resolve all conflicts of interest prior to this educational activity. 

Faculty Disclosure Statements

In accord with the disclosure policy of The Society for Translational Oncology (STO) as well as guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.


Independent Peer Reviewer Disclosure

Reviewer “A” discloses no relevant financial relationships.


Planner Disclosures

The following planners and/or their spouse/partner have reported no relevant financial relationship with a commercial interest:

Robert J. Birnbaum, MD, PhD
Anan Nathif, EdM
Gabby Cruze
Carol Hardman

The following planners and/or their spouse/partner have reported a relevant financial relationship with a commercial interest:

Beverly Moy, MD
Consulting: GlaxoSmithKline, Pfizer

Updated: 10/3/2012


Speaker Disclosures 

The following speakers and/or their spouse/partner have reported a relevant financial relationship with a commercial interest:

Beverly Moy, MD
Consulting: GlaxoSmithKline, Pfizer

Updated: 10/3/2012


Educational Support

This program has received support in the form of educational grants from the following companies:
  • Genentech
  • Genomic Health
  • Novartis

Hardware/Software Specifications

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration

Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements

Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: 
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit


Privacy Policy

Please click here to review our privacy policy.